Insider Selling: DexCom (NASDAQ:DXCM) Director Sells $549,537.56 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the completion of the transaction, the director owned 29,293 shares in the company, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Monday, September 14th, Nicholas Augustinos sold 1,550 shares of DexCom stock. The shares were sold at an average price of $84.02, for a total value of $130,231.00.

DexCom Stock Up 1.6%

DXCM opened at $89.35 on Friday. The company has a market cap of $33.72 billion, a P/E ratio of 35.32, a P/E/G ratio of 1.47 and a beta of 1.42. The business’s 50-day moving average price is $84.10 and its 200-day moving average price is $73.28. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the prior year, the business posted $0.48 EPS. DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, equities analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Mizuho upped their price target on shares of DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Wells Fargo & Company increased their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price on the stock. Argus increased their price objective on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Canaccord Genuity Group set a $90.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.08.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently modified their holdings of DXCM. Norges Bank bought a new position in shares of DexCom in the 4th quarter worth approximately $483,356,000. Legal & General Group Plc bought a new stake in shares of DexCom during the second quarter valued at approximately $173,237,000. Deutsche Bank AG bought a new stake in shares of DexCom during the second quarter valued at approximately $164,035,000. Employees Provident Fund Board purchased a new stake in DexCom in the fourth quarter worth $145,352,000. Finally, J. Stern & Co. LLP grew its stake in DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after purchasing an additional 1,529,641 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.